MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)

Stock Information for MediciNova Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About MediciNova Inc.

MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)
MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND
MediciNova Provides Shareholder Update on Key Developments
MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference
MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial
MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million
MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials
MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.